研究目的
To investigate vascular changes of myopic choroidal neovascularization (mCNV) after ranibizumab treatment using optical coherence tomography-angiography (OCTA).
研究成果
The present study provided evidence of the efficacy of anti-VEGF therapy in the vascular remodeling of the mCNV with a reduction in the lesion area and in the presence of anastomoses, vascular loops, small capillary ramifications, and feeder vessels. In particular, the closure of the feeder vessel seems to play a role as a good prognostic factor. OCTA is a new tool and provides useful and additional information; however, its precise role needs further development.
研究不足
The absence of a monthly monitoring by OCTA prevented us from temporally placing the closure of the feeder vessel during the 6 months of follow-up and determining whether the same closure was permanent or subject to an opening and closing mechanism. An obvious and additional limitation of our study is the small sample size and the statistical inference that results from that.
1：Experimental Design and Method Selection:
Consecutive subjects with a diagnosis of mCNV were included. Patients underwent intravitreal injection of ranibizumab treatment with a 6-month follow-up. All patients underwent a complete ophthalmological examination and OCTA evaluation. The 3 × 3 OCTA en face images were analyzed for the absence/presence of mCNV, CNV area, and CNV network morphology.
2：Sample Selection and Data Sources:
Patients affected by mCNV secondary to PM were considered for this prospective study over a 6-month follow-up period.
3：List of Experimental Equipment and Materials:
SD-OCT (Heidelberg Spectralis version 1.9.10.0; Heidelberg Engineering, Heidelberg, Germany), OCTA (RTVue XR with AnigoVue (Optovue, Inc., Fremont, CA, USA), IOL MASTER (Carl Zeiss Meditec, Inc., Dublin, CA, USA), color fundus photography (TRC-NW8F; TopCon Corp., Tokyo, Japan).
4：0; Heidelberg Engineering, Heidelberg, Germany), OCTA (RTVue XR with AnigoVue (Optovue, Inc., Fremont, CA, USA), IOL MASTER (Carl Zeiss Meditec, Inc., Dublin, CA, USA), color fundus photography (TRC-NW8F; TopCon Corp., Tokyo, Japan).
Experimental Procedures and Operational Workflow:
4. Experimental Procedures and Operational Workflow: After the first ranibizumab 0.5-mg injection all patients were treated according to a pro re nata regimen and retreatment criteria were new hemorrhage, signs of mCNV activity on SD-OCT, along with metamorphopsia and decrease in BCVA during follow-up.
5：5-mg injection all patients were treated according to a pro re nata regimen and retreatment criteria were new hemorrhage, signs of mCNV activity on SD-OCT, along with metamorphopsia and decrease in BCVA during follow-up.
Data Analysis Methods:
5. Data Analysis Methods: Statistical analysis was performed with SPSS Software (v.25 2019; IBM, Italy). Changes in BCVA, central retinal thickness, selected CNV area, and vessel areas were compared with baseline using ANOVA.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
